Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia.

Bejanyan N, Fu AZ, Lazaryan A, Fu R, Kalaycio M, Advani A, Sobecks R, Copelan E, Maciejewski JP, Sekeres MA.

Cancer. 2010 Aug 1;116(15):3614-20. doi: 10.1002/cncr.25086.

2.

Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.

Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F, Ghielmini M.

Tumori. 2009 May-Jun;95(3):303-10.

3.

Outcomes of weekend admissions for upper gastrointestinal hemorrhage: a nationwide analysis.

Ananthakrishnan AN, McGinley EL, Saeian K.

Clin Gastroenterol Hepatol. 2009 Mar;7(3):296-302e1. doi: 10.1016/j.cgh.2008.08.013. Epub 2008 Aug 19.

PMID:
19084483
4.
5.

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.

Cancer Res. 1998 Sep 15;58(18):4173-9.

6.

Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes.

Horwich TB, Hernandez AF, Liang L, Albert NM, Labresh KA, Yancy CW, Fonarow GC; Get With Guidelines Steering Committee and Hospitals.

Am Heart J. 2009 Sep;158(3):451-8. doi: 10.1016/j.ahj.2009.06.025. Epub 2009 Aug 4.

PMID:
19699870
7.
8.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754
9.

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.

Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN.

Cancer. 2000 May 1;88(9):2037-41.

PMID:
10813714
10.

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I, Hunault-Berger M, Recher C, Lioure B, Himberlin C, Escoffre-Barbe M, Berthou C, Lissandre S, Fegueux N, Cahn JY, Jourdan E, Dreyfus F, Reiffers J, Milpied N, Ifrah N.

J Clin Oncol. 2010 Jun 20;28(18):3028-34. doi: 10.1200/JCO.2009.26.4648. Epub 2010 May 17.

PMID:
20479424
11.

Long-term outcomes of de novo acute myeloid leukemia in Thai patients.

Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.

J Med Assoc Thai. 2009 Sep;92(9):1143-9.

PMID:
19772172
12.

Do weekends or evenings matter in a pediatric intensive care unit?

Hixson ED, Davis S, Morris S, Harrison AM.

Pediatr Crit Care Med. 2005 Sep;6(5):523-30.

PMID:
16148810
13.

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.

Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R.

Int J Hematol. 2010 Mar;91(2):276-83. doi: 10.1007/s12185-009-0480-5.

PMID:
20054669
14.

Hospital care for patients experiencing weekend vs weekday stroke: a comparison of quality and aggressiveness of care.

Kazley AS, Hillman DG, Johnston KC, Simpson KN.

Arch Neurol. 2010 Jan;67(1):39-44. doi: 10.1001/archneurol.2009.286.

PMID:
20065127
15.

Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.

PMID:
12537972
16.

[Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].

Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX.

Zhonghua Xue Ye Xue Za Zhi. 2005 Dec;26(12):705-9. Chinese.

PMID:
16620570
17.

The benefit of induction chemotherapy in patients age > or = 75 years.

Vey N, Coso D, Bardou VJ, Stoppa AM, Braud AC, Bouabdallah R, Sainty D, Mozziconacci MJ, Lafage M, Damaj G, Blaise D, Gastaut JA, Maraninchi D.

Cancer. 2004 Jul 15;101(2):325-31.

18.

Weekend versus weekday admission and mortality from gastrointestinal hemorrhage caused by peptic ulcer disease.

Shaheen AA, Kaplan GG, Myers RP.

Clin Gastroenterol Hepatol. 2009 Mar;7(3):303-10. doi: 10.1016/j.cgh.2008.08.033. Epub 2008 Sep 3.

PMID:
18849015
19.

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.

Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S.

Blood. 2009 Nov 5;114(19):4027-33. doi: 10.1182/blood-2009-06-229351. Epub 2009 Aug 26.

20.

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A.

Blood. 1999 Jun 15;93(12):4116-24.

Supplemental Content

Support Center